Vicore Pharma Holding AB Sponsored ADR(VCRE)
$9.90-0.22 (-2.17%)
VCRE
Vicore Pharma Holding AB Sponsored ADR financials statements
$9.90
At close:-0.22 (-2.17%)
Vicore Pharma Holding AB Sponsored ADR (VCRE) Ratios
3 Followers
Vicore Pharma Holding AB Sponsored ADR Ratios
VCRE's free cash flow for Q3 2026 was kr-137.47M. For the 2026 fiscal year, VCRE's free cash flow was increased by kr0.00 and operating cash flow was kr-137.47M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 10.28 |
| Quick Ratio | 10.28 |
| Cash Ratio | 4.88 |
| Solvency Ratio | -3.88 |
| Operating Cash Flow Ratio | -3.17 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | kr 1.09B |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.00 |
| Debt-to-Equity Ratio | 0.00 |
| Debt-to-Capital Ratio | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | 1.11 |
| Debt Service Coverage Ratio | -7956.90 |
| Interest Coverage Ratio | -7574.08 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.00 |
| Net Debt to EBITDA | 1.21 |
| Profitability Margins | |
| Gross Profit Margin | 100.00% |
| EBIT Margin | -12507.57% |
| EBITDA Margin | -12507.57% |
| Operating Profit Margin | -11905.82% |
| Pretax Profit Margin | -12509.14% |
| Net Profit Margin | -12509.14% |
| Continuous Operations Profit Margin | -12509.14% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 105.07% |
| Return on Assets (ROA) | -39.18% |
| Return on Equity (ROE) | -43.59% |
| Return on Capital Employed (ROCE) | -41.31% |
| Return on Invested Capital (ROIC) | -41.31% |
| Return on Tangible Assets | -39.18% |
| Earnings Yield | -13.29% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -15.66 |
| Free Cash Flow Per Share | -15.66 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 |
| Operating Cash Flow to Sales Ratio | -98.44 |
| Free Cash Flow Yield | -10.46% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -68.09 |
| Price-to-Sales (P/S) Ratio | 941.48 |
| Price-to-Book (P/B) Ratio | 3.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.56 |
| Price-to-Operating Cash Flow Ratio | -9.56 |
| Price-to-Earnings Growth (PEG) Ratio | -0.68 |
| Enterprise Value Multiple | -6.32 |
| Enterprise Value | 3.02B |
| EV to EBITDA | -6.32 |
| EV to Sales | 790.02 |
| EV to Free Cash Flow | -8.03 |
| EV to Operating Cash Flow | -8.03 |
| Tangible Book Value Per Share | 45.67 |
| Shareholders’ Equity Per Share | 45.67 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.16 |
| Net Income Per Share | -19.90 |
| Tax Burden | 1.00 |
| Interest Burden | 1.00 |
| Research & Development to Revenue | 102.27 |
| SG&A to Revenue | 17.79 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.83 |
Currency in SEK

